Bruker (BRKR) Projected to Post Quarterly Earnings on Tuesday

Bruker (NASDAQ:BRKR) will likely be releasing its earnings data before the market opens on Tuesday, February 11th. Analysts expect Bruker to post earnings of $0.75 per share and revenue of $965.61 million for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Bruker Stock Performance

NASDAQ BRKR opened at $55.59 on Monday. The company has a fifty day moving average of $58.32 and a two-hundred day moving average of $61.04. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.66 and a quick ratio of 0.73. Bruker has a 1 year low of $48.07 and a 1 year high of $94.86. The company has a market capitalization of $8.43 billion, a PE ratio of 26.73, a P/E/G ratio of 3.81 and a beta of 1.16.

Bruker Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, December 16th. Shareholders of record on Monday, December 2nd were given a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 0.36%. The ex-dividend date was Monday, December 2nd. Bruker’s dividend payout ratio (DPR) is 9.62%.

Insider Buying and Selling

In other news, CEO Frank H. Laukien bought 100,000 shares of the stock in a transaction on Monday, November 18th. The shares were bought at an average price of $50.14 per share, with a total value of $5,014,000.00. Following the completion of the acquisition, the chief executive officer now owns 38,439,563 shares of the company’s stock, valued at approximately $1,927,359,688.82. This trade represents a 0.26 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 28.30% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research analysts have issued reports on BRKR shares. The Goldman Sachs Group raised shares of Bruker from a “sell” rating to a “neutral” rating and set a $60.00 price objective on the stock in a research report on Thursday, December 5th. Citigroup dropped their price target on Bruker from $80.00 to $75.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. UBS Group assumed coverage on Bruker in a research note on Tuesday, December 10th. They issued a “neutral” rating and a $66.00 target price on the stock. Wells Fargo & Company dropped their target price on Bruker from $78.00 to $75.00 and set an “overweight” rating on the stock in a report on Wednesday, November 6th. Finally, TD Cowen lowered their price objective on shares of Bruker from $72.00 to $70.00 and set a “hold” rating on the stock in a research report on Wednesday, November 6th. Six research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $74.45.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.